Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., is a fully integrated, global biosimilars company committed to transforming healthcare and transforming lives by enabling affordable access to biosimilars for millions of patients worldwide. It is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes.

Biocon Biologics has commercialized eight biosimilars globally and has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology.

Biocon was founded by Kiran Mazumdar-Shaw, a first-generation entrepreneur who started her biotech business in 1978 in India and built a global business with over 4 decades of experience in biotechnology, contributing to offer accessible and affordable treatments to millions of patients worldwide.

Biocon Biologics was founded in 2019, and in 2023 it acquired Viatris’ global biosimilars business to become a fully integrated global biosimilars company with end-to-end capabilities from “lab-to-market” and a broad portfolio.

Biocon Biologics is focused on accelerating growth for existing products while simultaneously expanding its geographical footprint and launching new products.

Visit Website: www.bioconbiologicseu.com